- $85.44m
- $58.88m
- $12.13m
- 45
- 27
- 13
- 18
2019 December 31st | C2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.67 | 11.6 | 13.2 | 11.8 | 12.1 |
Cost of Revenue | |||||
Gross Profit | -4.41 | 0.598 | 1.57 | 1.48 | -2.63 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 33.2 | 29.4 | 53.1 | 54.1 | 64.4 |
Operating Profit | -26.6 | -17.8 | -40 | -42.2 | -52.3 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -26.5 | -18 | -40.4 | -40.8 | -50.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -26.5 | -18 | -40.4 | -40.8 | -50.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -26.5 | -18 | -40.4 | -40.8 | -50.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -28.4 | -20 | -40.4 | -40.8 | -50.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.936 | -0.557 | -0.656 | -0.637 | -0.756 |